CRASH Trials: Key Findings and Differences
The CRASH trials represent landmark studies on tranexamic acid (TXA) in trauma: CRASH-2 demonstrated mortality reduction in bleeding trauma patients when given within 3 hours, CRASH-3 showed benefit specifically in mild-to-moderate traumatic brain injury (TBI) when treated early, while CRASH-1 examined corticosteroids in head injury and found no benefit (leading to recommendations against steroid use in major trauma). 1, 2, 3
CRASH-2 Trial: TXA in Bleeding Trauma
Primary Focus: Extracranial hemorrhage in trauma patients
Key Findings:
- Reduced overall mortality by 1.5% and bleeding deaths by one-third when administered appropriately 1
- Critical time window: Treatment within 3 hours of injury reduces bleeding deaths, but treatment after 3 hours actually increases mortality risk 4
- The time-dependent effect is not explained by injury type, blood pressure, or presence of head injury—it's purely about timing 4
- Established the standard TXA dosing: 1g bolus over 10 minutes, followed by 1g infusion over 8 hours 1
Clinical Application:
- Should be given to any bleeding trauma patient or those at risk of significant bleeding
- Must be administered as soon as possible, ideally en route to hospital
- Do not wait for viscoelastic assessment results before giving TXA 1
CRASH-3 Trial: TXA in Traumatic Brain Injury
Primary Focus: Isolated TBI with intracranial bleeding (n=12,737 patients, with 9,202 treated within 3 hours) 3
Key Findings:
- Benefit limited to mild-to-moderate TBI: Risk ratio 0.78 (95% CI 0.64-0.95) for head injury-related death 3
- No benefit in severe TBI (GCS 3-8): Risk ratio 0.99 (95% CI 0.91-1.07) 3
- When excluding moribund patients (GCS=3 or bilateral unreactive pupils), the benefit became clearer: 12.5% mortality with TXA vs 14.0% with placebo 3
- Early treatment is critical: The benefit was strongest within 2 hours and diminished rapidly thereafter, though patients with severe TBI (GCS <9) may benefit beyond 3 hours 5
- TXA reduced early deaths (within 24 hours) by 26% in non-moribund TBI patients (RR 0.74,95% CI 0.58-0.94) 6
Safety Profile:
- No increase in vascular occlusive events (RR 0.98) or seizures (RR 1.09) 3
- However, prolonged use beyond 1 day or delayed administration beyond 8 hours increases thromboembolic risk 7
CRASH-1: Corticosteroids in Head Injury
Primary Focus: Corticosteroid use in major trauma and TBI
Key Findings:
- No mortality benefit: Risk ratio 1.00 (95% CI 0.89-1.13) across 19 trials with 12,269 patients 2
- No dose-dependent effect observed (low vs high dose corticosteroids showed similar lack of benefit) 2
- No increase in gastrointestinal bleeding or superinfection, but potential for clinically important side effects 2
Current Recommendation:
- Corticosteroids are NOT recommended for major trauma (conditional recommendation, low quality evidence) 2
- This contrasts with their use in ARDS, where methylprednisolone has a role 2
Critical Clinical Distinctions
Time Windows:
- CRASH-2 and CRASH-3 both emphasize treatment within 3 hours, with optimal benefit within 2 hours 1, 5
- Treatment after 3 hours may cause harm in bleeding trauma 4
- Severe TBI patients (GCS <9) may benefit beyond the 2-hour window 5
Patient Selection:
- Bleeding trauma (CRASH-2): Any significant extracranial hemorrhage
- TBI (CRASH-3): Mild-to-moderate head injury (GCS 9-15 or GCS <9 if pupils reactive)
- Avoid in moribund patients: Those with GCS=3 and bilateral unreactive pupils show no benefit 3, 6
Contraindications from FDA labeling:
- Absolute contraindication in subarachnoid hemorrhage due to cerebral edema and infarction risk 8
- Active intravascular clotting 8
- Severe hypersensitivity reactions 8
Practical Algorithm
For bleeding trauma patients:
- Administer TXA immediately if within 3 hours of injury
- Use standard dosing: 1g bolus + 1g infusion over 8 hours
- Do not delay for laboratory results
For isolated TBI patients:
- Assess GCS and pupillary reactivity
- If GCS 9-15 or GCS <9 with reactive pupils AND within 3 hours: give TXA
- If GCS=3 with bilateral unreactive pupils: withhold TXA (no benefit)
- Prioritize treatment within 2 hours when possible
Avoid:
- TXA administration beyond 3 hours in bleeding trauma (may increase mortality)
- Prolonged TXA use beyond 24 hours (increases thromboembolic risk)
- Corticosteroids in trauma (no benefit, potential harm)